Breast Cancer Research and Treatment

Papers
(The TQCC of Breast Cancer Research and Treatment is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium232
Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic150
Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–201778
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, T67
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies58
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer56
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 201854
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer54
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment54
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival52
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer51
Evaluation and management of insomnia in women with breast cancer50
International variation in breast cancer incidence and mortality in young women50
Management of brain metastases in breast cancer: a review of current practices and emerging treatments46
Body composition and breast cancer risk and treatment: mechanisms and impact44
Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors42
High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis42
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer42
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study41
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence40
Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City40
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns37
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial33
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer33
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer32
Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis32
Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers31
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome31
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)31
The role of Micro-CT in imaging breast cancer specimens31
Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China30
Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response30
Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner30
Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging30
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors29
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score29
Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women28
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy a28
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer28
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies28
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–201528
Immune microenvironment in different molecular subtypes of ductal breast carcinoma27
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)27
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study27
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study27
Behavior of metastatic breast cancer according to subtype27
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial27
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial26
Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery26
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database26
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype26
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients25
Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes25
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer24
The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer24
The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer24
Spatial location of local recurrences after mastectomy: a systematic review24
Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis23
Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no speci23
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study23
A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers23
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, place23
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes23
Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy23
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer23
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors23
TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway23
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer22
Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells22
Immunotherapy toxicity: identification and management22
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers22
Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer22
Association between thyroid gland diseases and breast cancer: a case–control study22
Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts22
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer22
Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis22
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience21
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population21
Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography21
Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet21
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression20
NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis20
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients20
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study20
Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers20
Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile20
Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database20
Characterization of estrogen receptor-low-positive breast cancer20
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis20
ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells20
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol20
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast 19
Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases19
Hormone replacement therapy and mammographic density: a systematic literature review19
Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors19
Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?19
The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review19
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway19
Clinical trials of immunotherapy in triple-negative breast cancer19
Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer19
Outcomes following lymphaticovenous anastomosis (LVA) for 100 cases of lymphedema: results over 24-months follow-up19
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical19
HER2-targeted therapy influences CTC status in metastatic breast cancer19
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic19
Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival19
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study18
COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic18
Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?18
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study18
Sensory profiles in women with neuropathic pain after breast cancer surgery18
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer18
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer18
The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis18
Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer18
Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients18
Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up18
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer18
Width of margins in phyllodes tumors of the breast: the controversy drags on?—a systematic review and meta-analysis18
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer18
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy18
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors18
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific sub18
Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells18
Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients17
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer17
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors17
Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence17
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-ins17
PIK3CA-mutations in breast cancer17
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer17
Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis17
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer17
Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period17
Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells17
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function17
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)17
Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer17
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies17
Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy16
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes16
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation16
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach16
Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study16
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer16
Trends in heart disease mortality among breast cancer survivors in the US, 1975–201716
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer16
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system16
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer16
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer16
A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer16
Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study16
Predictive risk factors of complications in different breast reconstruction methods16
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study16
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase16
Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study16
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer16
Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model16
Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis16
Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience15
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors15
The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative15
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer15
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment15
Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women15
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management15
SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study15
Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis15
Breast cancer resistance mechanisms: challenges to immunotherapy15
Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial15
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA15
Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer15
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients15
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity15
Medical costs associated with metastatic breast cancer in younger, midlife, and older women15
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years 15
Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative15
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review15
Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer15
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer14
A systematic review of multimodal prehabilitation in breast cancer14
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer14
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)14
Implications of missing data on reported breast cancer mortality14
Ultrasound visibility of select breast biopsy markers for targeted axillary node localization following neoadjuvant treatment: simulation using animal tissue models14
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer14
Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)14
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer14
A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity14
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning14
Stage-specific survival has improved for young breast cancer patients since 2000: but not equally14
Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution14
LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis14
Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population14
COVID-19 vaccination and breast cancer surgery timing14
Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study14
Carbon ion radiation therapy in breast cancer: a new frontier14
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer14
The shape of breast cancer14
FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact14
A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women13
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant system13
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen13
The epithelial sodium channel has a role in breast cancer cell proliferation13
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer13
Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation13
Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery13
Radial scars and complex sclerosing lesions on core needle biopsy of the breast: upgrade rates and long-term outcomes13
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research13
Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts13
Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction13
Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)13
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer13
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey13
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer13
Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?13
Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts13
High serum levels of periostin are associated with a poor survival in breast cancer13
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade13
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients13
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer13
Presentation and characteristics of breast cancer in young women under age 4013
Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes13
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial13
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanc13
Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors12
Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database12
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis12
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy12
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes12
Standardization of the tumor-stroma ratio scoring method for breast cancer research12
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer12
M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma12
Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy12
A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients12
Patient preferences for locoregional therapy in early-stage breast cancer12
Low RAI2 expression is a marker of poor prognosis in breast cancer12
Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population12
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients12
Tumor subtypes and survival in male breast cancer12
High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer12
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy12
Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer12
The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors12
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metasta12
UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin12
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?12
The WISDOM study: a new approach to screening can and should be tested12
Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis12
Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method12
Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study12
0.026124954223633